Wright Medical Group N.V

Wright Medical — Tornier — Investor Presentation (January 2014)

22 slides from Wright Medical's investor presentation, Jan 13, 2014

  1. Slide 1: Investor Presentation 2014

    Investor Presentation 2 0 1 4 Exhibit 99.2

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS Statements contained in this presentation that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations of future events and often can be ident

  3. Slide 3: Non GAAP Financial Measures

    NON GAAP FINANCIAL MEASURES Tornier uses certain non-GAAP financial measures in this presentation, such as adjusted EBITDA, adjusted gross margin and constant currency. Tornier uses non-GAAP financial measures as supplemental measures of performance and believes these measures provide useful informa

  4. Slide 4: Global medical device company focused on extremities

    TORNIER IS… Global Medical Device Company, focusing on providing superior solutions to surgeons treating extremities injuries & disorders

  5. Slide 5: [@)

    TORNIER [@)

  6. Slide 6: Well-positioned for long-term growth: high growth market

    TORNIER IS WELL-POSITIONED FOR LONG-TERM GROWTH HIGH GROWTH MARKET UPPER EXTREMITIES Extremities Robust Drivers Enable Sustained Growth $6.5B 8-9% CAGR (’14 – ’18) Based upon management estimates Leader in Innovation, Science & Education Aligned to the Extremity Call Point FOCUSED ON EXECUTION Upper

  7. Slide 7: Tornier is focused on robust, high-growth markets

    9-10% CAGR LOWER EXTREMITIES TORNIER IS FOCUSED ON ROBUST, HIGH-GROWTH MARKETS UPPER EXTREMITIES 8-9% CAGR Tornier’s Available Market is $6.5B with a 8 - 9% CAGR $1.7B $2.8B $2.7B $3.7B

  8. Slide 8: Extremity market drivers provide opportunity for sustained growth

    EXTREMITY MARKET DRIVERS PROVIDE OPPORTUNITY FOR SUSTAINED GROWTH • Aging population • Growing awareness (globally) • “Quality of life” expectations • Extremities specific design • Unmet need for early intervention • Growing need for revision TECHNOLOGY PATIENTS OUTCOMES • Improving clinical outcome

  9. Slide 9: Well-positioned for long-term growth: comprehensive product portfolio

    TORNIER IS WELL-POSITIONED FOR LONG-TERM GROWTH COMPREHENSIVE PRODUCT PORTFOLIO UPPER EXTREMITIES LOWER EXTREMITIES Based upon management estimates Leader in Innovation, Science & Education Robust Drivers Enable Sustained Growth $6.5B 8-9% CAGR (’14 – ’18) FOCUSED ON EXECUTION Aligned to the Extremi

  10. Slide 10: Comprehensive portfolio provides full-line support to the extremity surgeon

    COMPREHENSIVE PORTFOLIO PROVIDES FULL-LINE SUPPORT TO THE EXTREMITY SURGEON JOINT REPLACEMENTS BONE REPAIR BIOLOGICS SOFT TISSUE REPAIR 96 Distinct Extremities Products Number of Extremities Products: UPPER Shoulder, Elbow, Hand & Wrist LOWER Foot & Ankle PROCEDURES

  11. Slide 11: Portfolio strategy leverages strengths to take share

    PORTFOLIO STRATEGY LEVERAGES STRENGTHS TO TAKE SHARE WHILE EXPANDING EXTREMITY MARKETS JOINT REPLACEMENTS BONE REPAIR BIOLOGICS SOFT TISSUE REPAIR 1. Take Share through introduction of best-in-class extremity specific solutions 2. Expand arthroplasty markets with early intervention products 3. Creat

  12. Slide 12: Slide 12

  13. Slide 13: The go-to extremities company with leading science and education programs

    TORNIER IS THE “GO-TO” EXTREMITIES COMPANY WITH INDUSTRY LEADING SCIENCE & EDUCATION PROGRAMS RESPECTED FOR SCIENTIFIC RIGOR SUPPORTING ACTIVE FUNDAMENTAL RESEARCH • Pyrolytic carbon • Advanced kinematic & biomechanical testing capability • Computer aided surgery / 3D operative planning COMMITTED TO

  14. Slide 14: Well-positioned for long-term growth: focused for efficient sales

    TORNIER IS WELL-POSITIONED FOR LONG-TERM GROWTH HIGH GROWTH MARKET FOCUSED FOR EFFICIENT SALES COMPREHENSIVE PRODUCT PORTFOLIO Robust Drivers Enable Sustained Growth $6.5B 7-9% CAGR (’14 – ’18) Aligned to the Extremity Call Point FOCUSED ON EXECUTION Based upon management estimates Leader in Innovat

  15. Slide 15: Conducts international sales operations in countries on 6 continents

    TORNIER CONDUCTS INTERNATIONAL SALES OPERATIONS IN 45 DISTINCT COUNTRIES ON 6 CONTINENTS Primarily direct sales Primarily distributor Mixed Model Country Office International revenue $93.3 MM (41% of Total)* * Q3 2013 year to date revenue results

  16. Slide 16: Three strategic initiatives to strengthen international business

    THREE STRATEGIC INITIATIVES TO STRENGTHEN OUR INTERNATIONAL BUSINESS STRENGTHEN BRAND IN EMERGING MARKETS 3 ACCELERATE REVENUE GROWTH 2 DRIVE ADOPTION IN DEVELOPED GEOGRAPHIES 1 • Aggressively launch new platform products globally (ex. Ascend Flex) • Broaden product offering in direct & distributor

  17. Slide 17: Continue to invest to build a superior U.S. sales force

    CONTINUE TO INVEST TO BUILD A SUPERIOR U.S. SALES FORCE Competitively Superior • Exclusive channel • Expanded portfolio • Narrow rep territories • Reps provide “value-add” DESIRED STATE Proficient & Productive • Reps aligned to Upper / Lower • Continue to fill territories • Certify rep training • Tr

  18. Slide 18: Completed significant transitions within U.S. sales channel in 2013

    COMPLETED SIGNIFICANT TRANSITIONS WITHIN U.S. SALES CHANNEL IN 2013 EXITING 2012 ENTERING 2014 Distributor Direct US Sales Network • 18 Legacy Tornier distributors selling both UE & LE • 3 Direct Tornier territories • 50 OrthoHelix LE agents in Oct-12 US Sales Network • U.S. revenue $134.2 MM (59% o

  19. Slide 19: Work remains to build a best-in-class U.S. sales force

    WORK REMAINS TO BUILD A “BEST-IN-CLASS” U.S. SALES FORCE Agreements & Alignment Distributor Negotiation US Sales Channel Transition Sales Mgmt. & Training Org. 4 4 4 Timing 2012 Desired State Rep Training & Education Performance & Productivity High Uncertainty Strong & Reliable Performance Territory

  20. Slide 20: Plans to deliver consistent above-market growth and strong financial performance

    Above Market CAGR Upper Extrm. 20% of Rev PLANS TO DELIVER CONSISTENT ABOVE-MARKET GROWTH AND STRONG FINANCIAL PERFORMANCE EBITDA Leverage 2018 2013 2013 2018 Lower Extrm. Projected Extremities Revenues • Driving above-market growth in upper and lower extremity segments • Revenue geographically bala

  21. Slide 21: Well-positioned for long-term growth

    TORNIER IS WELL-POSITIONED FOR LONG-TERM GROWTH FOCUSED ON EXECUTION Based upon management estimates

  22. Slide 22: Thank You

    THANK YOU

Tornier — Investor Presentation (January 2014) on 6ix